Definition and epidemiology
Fragile X syndrome (FXS) is an X-linked trinucleotide repeat disorder caused by expansion of a CGG repeat sequence in the 5' untranslated region of the FMR1 gene (Xq27.3). It is the most common inherited cause of intellectual disability and the most common known single-gene cause of autism spectrum disorder.
- Prevalence is approximately 1 in 4,000 to 1 in 7,000 males and about 1 in 6,000 to 1 in 11,000 females.
- Males are typically more severely affected than females because they have only one X chromosome (no normal allele to compensate).
- Carrier frequency of the premutation allele is relatively common in the general population, roughly 1 in 150-300 females and 1 in 400-850 males.
- Named historically for the cytogenetic appearance of a 'fragile' constriction near the end of the X chromosome under folate-deficient culture conditions (an older diagnostic method, now replaced by molecular testing).
- Most common inherited cause of intellectual disability and leading monogenic cause of autism
- Caused by CGG trinucleotide repeat expansion (>200 repeats) in FMR1 on Xq27.3
- Full mutation causes promoter hypermethylation and loss of FMRP protein
- Classic triad: long face, large ears, macroorchidism (post-pubertal)
- Diagnosis is molecular (PCR/Southern blot), not karyotype-based 'fragile site' testing
- Shows anticipation: repeat expands further with maternal transmission
- Premutation carriers risk FXTAS (tremor/ataxia, older males) and FXPOI (early menopause, females)
- No cure; management is supportive, educational, and symptom-targeted (ADHD, anxiety, behavior)
Etiology and risk factors
FXS results from an unstable expansion of CGG repeats in the FMR1 gene promoter region.
Repeat length categories
| Category | Repeat number | Phenotype |
|---|---|---|
| Normal | 5-44 | Unaffected |
| Intermediate | 45-54 | Unaffected, mild instability |
| Premutation | 55-200 | Usually unaffected cognitively; risk of FXTAS and primary ovarian insufficiency |
| Full mutation | >200 | Fragile X syndrome |
- Full mutation alleles become hypermethylated, silencing FMR1 transcription and eliminating FMRP production.
- Repeat expansion shows anticipation: premutation alleles tend to expand further when transmitted, especially through maternal (not paternal) meiosis.
- Risk factors are essentially genetic: maternal carrier status of a premutation or full mutation allele; family history of intellectual disability, autism, tremor/ataxia (FXTAS), or premature ovarian insufficiency in female relatives.
Pathophysiology
The FMR1 gene encodes FMRP (fragile X mental retardation protein), an RNA-binding protein that regulates translation of numerous mRNAs at synapses, many of which are critical for synaptic plasticity and dendritic spine maturation.
- CGG expansion beyond ~200 repeats leads to abnormal DNA methylation of the FMR1 promoter, silencing gene transcription.
- Loss of FMRP disrupts synaptic protein synthesis regulation, particularly downstream of metabotropic glutamate receptor 5 (mGluR5) signaling, leading to excessive and immature dendritic spines.
- This produces impaired synaptic pruning and plasticity, underlying the intellectual disability, hyperarousal, and sensory processing abnormalities seen clinically.
- Premutation carriers (55-200 repeats) do not have gene silencing but instead show toxic RNA gain-of-function effects from the expanded CGG transcript, which underlies FXTAS (fragile X-associated tremor/ataxia syndrome) in older carriers and FXPOI (primary ovarian insufficiency) in female carriers.
Clinical features
Clinical presentation varies with sex and repeat status; males with the full mutation are most severely affected.
Physical features (become more apparent with age, especially post-puberty)
- Long, narrow face with prominent jaw
- Large, protruding ears
- Macrocephaly
- Macroorchidism (enlarged testes), typically post-pubertal
- High-arched palate, hyperextensible joints, flat feet
- Mitral valve prolapse (connective tissue laxity)
Neurodevelopmental and behavioral features
- Intellectual disability, ranging from mild to severe (more pronounced in males)
- Speech and language delay
- Autism spectrum features: poor eye contact, hand flapping, perseverative speech, social anxiety
- Attention-deficit/hyperactivity disorder (ADHD), hyperactivity, impulsivity
- Anxiety, sensory hypersensitivity (sound, touch, light)
- Seizures in a minority of patients
Carrier females (full mutation)
- Often milder or absent intellectual disability due to the second, normal X allele (X-inactivation mosaicism)
- May have learning disabilities, shyness, or anxiety only
Premutation carriers (adult-onset)
- FXTAS: late-onset intention tremor and cerebellar ataxia, mainly in older male carriers
- FXPOI: primary ovarian insufficiency in female carriers
Diagnosis
Diagnosis is molecular, not clinical, because physical features may be subtle, especially before puberty.
- First-line test: PCR and Southern blot analysis of FMR1 CGG repeat number and methylation status — this is the definitive diagnostic test.
- Karyotype-based cytogenetic 'fragile site' testing is obsolete and should not be used.
- Testing is indicated in any child with unexplained developmental delay, intellectual disability, or autism spectrum disorder, particularly with a suggestive family history or physical features.
- Prenatal diagnosis (chorionic villus sampling or amniocentesis) and carrier testing of at-risk family members are available once a familial mutation is identified.
- Genetic counseling is essential given the X-linked inheritance pattern and anticipation phenomenon; counsel maternal relatives about premutation carrier risks (FXTAS, FXPOI) and recurrence risk in future pregnancies.
- Additional baseline workup in a newly diagnosed child: hearing and vision screening, developmental/cognitive assessment, cardiac evaluation (echocardiogram for mitral valve prolapse/aortic root), and ophthalmologic exam.
Differential diagnosis
- Autism spectrum disorder (idiopathic): overlapping behavioral phenotype but no CGG expansion; FMR1 testing distinguishes.
- Down syndrome: intellectual disability with distinct dysmorphism (upslanting palpebral fissures, single palmar crease) and trisomy 21 on karyotype.
- Prader-Willi syndrome: hypotonia, hyperphagia/obesity, intellectual disability; due to 15q11-q13 deletion/imprinting defect, not CGG expansion.
- Sotos syndrome: overgrowth, macrocephaly, learning disability; NSD1 gene mutation.
- Klinefelter syndrome (47,XXY): tall stature, hypogonadism, learning difficulties, but testes are small (not enlarged) and karyotype shows extra X.
- 22q11.2 deletion syndrome: developmental delay, cardiac defects, cleft palate; detected by microarray/FISH, not FMR1 testing.
Management
There is no cure or disease-modifying therapy currently approved; management is supportive and multidisciplinary, following consensus guidance from groups such as the American Academy of Pediatrics and the National Fragile X Foundation.
Core supportive management
- Early intervention and special education services tailored to individual cognitive profile
- Speech, occupational, and physical therapy
- Behavioral therapy (applied behavior analysis) for autism-spectrum behaviors
- Family genetic counseling, including testing and counseling of at-risk relatives
Pharmacologic therapy (targets comorbid symptoms, not the underlying gene defect)
- Stimulants or alpha-2 agonists for ADHD/hyperactivity symptoms
- Selective serotonin reuptake inhibitors (SSRIs) for anxiety
- Antipsychotics (e.g., aripiprazole, risperidone) for severe irritability or aggression
- Melatonin for sleep disturbance
Surveillance
- Regular developmental, cardiac (mitral valve prolapse), ophthalmologic, and hearing assessments
- Monitoring for seizures and scoliosis
Targeted molecular therapies (e.g., mGluR5 antagonists) have been studied in trials but have not demonstrated consistent clinical benefit and are not part of standard care.
Complications and prognosis
- Lifelong intellectual disability of variable severity; most affected males require lifelong support with activities of daily living and may need supervised living arrangements as adults.
- Behavioral and psychiatric comorbidities (anxiety, ADHD, autism) often persist into adulthood and significantly affect quality of life and schooling/employment.
- Mitral valve prolapse and joint laxity are usually benign but warrant periodic cardiac follow-up.
- Seizures occur in a minority and are usually manageable with standard antiepileptic therapy.
- Premutation carriers face distinct, later-life risks: FXTAS (progressive tremor/ataxia, usually after age 50, mainly in males) and FXPOI (early menopause/infertility in females).
- Life expectancy is not significantly reduced; prognosis for independence correlates with degree of intellectual disability and access to early intervention.
FRAGILE: Face long, Retardation (intellectual disability), Autism features, Giant testes (macroorchidism), Inherited X-linked, Large ears, Expands with each generation (anticipation).
Practice questions
1. A 4-year-old boy presents with developmental delay, poor eye contact, and hand-flapping behaviors. On examination, he has a long face, large protruding ears, and macrocephaly. Which of the following is the most appropriate confirmatory diagnostic test?
2. A 55-year-old man, the maternal uncle of a boy recently diagnosed with Fragile X syndrome, develops progressive intention tremor and gait ataxia. Genetic testing reveals an FMR1 CGG repeat count of 90. Which mechanism best explains his neurological symptoms?
3. A couple seeks genetic counseling after their son is diagnosed with Fragile X syndrome. The mother is found to carry a premutation allele (70 CGG repeats). Which statement about inheritance risk is most accurate?
Frequently asked questions
What causes Fragile X syndrome?
Fragile X syndrome is caused by an expansion of a CGG trinucleotide repeat sequence beyond 200 copies in the FMR1 gene on the X chromosome. This expansion triggers hypermethylation of the gene's promoter, silencing FMR1 and preventing production of FMRP, a protein required for normal synaptic development. It is inherited in an X-linked pattern with a tendency for the repeat to expand further across generations, especially through the mother.
What are the first signs of Fragile X syndrome?
The earliest signs are usually developmental delays in speech, motor skills, and social interaction, often noticed in infancy or toddlerhood before distinctive physical features appear. Hypotonia, poor eye contact, and sensory sensitivities may be early clues. Characteristic facial features (long face, large ears) and macroorchidism typically become more noticeable only after puberty, so early diagnosis relies on developmental concerns prompting genetic testing.
How is Fragile X syndrome diagnosed?
Fragile X syndrome is diagnosed with a specific molecular blood test, usually PCR combined with Southern blot analysis, that measures the number of CGG repeats in the FMR1 gene and assesses methylation status. This test is recommended for any child with unexplained developmental delay, intellectual disability, or autism spectrum disorder. The older chromosome-based 'fragile site' test is outdated and no longer used.
Is Fragile X syndrome curable?
No, Fragile X syndrome is not curable because it stems from a permanent genetic change in the FMR1 gene. Treatment instead focuses on managing symptoms through early intervention, special education, speech and occupational therapy, and medications for associated anxiety, ADHD, or behavioral issues. With comprehensive support, many individuals achieve meaningful improvements in function and quality of life, though intellectual disability generally persists lifelong.
Fragile X syndrome vs autism spectrum disorder — what is the difference?
Fragile X syndrome is a specific genetic condition caused by an FMR1 gene mutation that can produce autism-like behaviors as one feature among many, including intellectual disability and distinct physical traits. Idiopathic autism spectrum disorder, by contrast, has no identified single genetic cause in most cases and lacks the physical and genetic markers of Fragile X. Genetic testing distinguishes the two, and Fragile X is actually the most common known single-gene cause of autism.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: Q99.2
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.